# Riboflavin, MTHFR C677T, and Blood Pressure: The Targeted Trial Signal > 1.6 mg riboflavin helped 677TT hypertensives in trials—not a cure for “MTHFR disease.” *Published 2026-07-10 · Updated 2026-07-10 · By Marcus Chen* In short In **MTHFR 677TT hypertensives**, targeted trials found **~1.6 mg/day riboflavin** lowered systolic BP (~5–6 mm Hg class effect in Wilson 2013). Mechanism: FAD cofactor support of thermolabile MTHFR. This is adjunctive, genotype-specific signal—not a mandate for mass MTHFR testing or a substitute for guideline HTN care. One of the few MTHFR stories with randomized blood-pressure data is also one of the most over-generalized. Keep the genotype, dose, and endpoint glued together. *This article is informational and editorial only. It is not medical advice, diagnosis, or a treatment plan. Numbers and literature ranges cited here are not personal prescriptions. Consult a qualified clinician before changing medications, supplements, diet, equipment, or management of a diagnosed condition. Seek urgent care for emergencies.* ## What is the biological rationale? MTHFR uses FAD. Riboflavin deficiency or suboptimal status may unmask thermolabile 677TT dysfunction more than in CC genotypes. Homocysteine and blood pressure associations with 677TT appear in literature with partial independence in some analyses—do not collapse everything into a single Hcy narrative. EGRac (erythrocyte glutathione reductase activation coefficient) is a functional riboflavin status tool used in research more than in routine primary care. ## What did Wilson et al. actually test? Genotype-stratified randomized designs in hypertensives, riboflavin ~1.6 mg/day, multi-week duration, blood-pressure endpoints alongside metabolic measures. 2012–2013 publications describe TT-specific responsiveness and follow-up patterns where TT patients remained more difficult to control until riboflavin was addressed in study framing. Sample sizes are modest relative to mega-HTN outcomes trials—effect is interesting, not omnipotent. Key reference points ParameterTrial-linked valueNote Genotype focus677TTNot all MTHFR variants Riboflavin dose~1.6 mg/dayModest, not mega Duration~16 weeks classStudy-specific SBP effect~−5.6 mm HgTT hypertensives, key analysis ## How should clinicians and patients use this without hype? Optimize riboflavin intake from food; consider modest supplementation if TT genotype is known and HTN is present—as adjunct conversation. Do not stop antihypertensives because B2 is “natural.” Do not test every normotensive person for MTHFR to sell B2. Dual-source: primary Hypertension/AJCN papers vs methylation-clinic brochures that promise multi-disease cures. ## What related claims remain weaker? Extrapolating mm Hg benefits to all MTHFR genotypes. Using BP data to justify routine thrombophilia-style MTHFR panels (ACMG utility cautions still apply for many indications). Bundling riboflavin into proprietary “methylation megacomplexes” at unclear doses with unproven composite outcomes. Sources: [Wilson et al. Hypertension 2013](https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.111.01047); [Wilson et al. AJCN 2012 follow-up](https://pubmed.ncbi.nlm.nih.gov/22277556/); [CDC MTHFR folic acid](https://www.cdc.gov/folic-acid/data-research/mthfr/index.html). Readers should dual-source primary literature, translate slogans into exposure units and effect sizes, and rank interventions by expected value under uncertainty. Cheap reversible steps often outrank extreme protocols. Opportunity cost is real: hours spent on unvalidated tests are hours not spent on sleep, training, protein adequacy, and primary care. Sex, life stage, comorbidities, medications, and geography change interpretation. Prefer falsifiable claims with named endpoints over multi-disease cure lists. Update beliefs when stronger trials appear rather than freezing identity around a single paper or influencer narrative. Measured curiosity beats both panic and complacency. Further reading should prioritize primary sources and consensus documents over secondary social summaries. When evidence is mixed, state both the signal and the limits in the same paragraph. When evidence is strong, still avoid overclaiming universality across populations. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. Context, dose, endpoint, and population must travel together; slogans that drop any of those four are not finished claims. ## Sources 1. [Wilson et al. Hypertension 2013](https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.111.01047) 2. [Wilson et al. AJCN 2012 follow-up](https://pubmed.ncbi.nlm.nih.gov/22277556/) 3. [CDC MTHFR folic acid](https://www.cdc.gov/folic-acid/data-research/mthfr/index.html) --- Source: https://healthcanon.com/hormones-and-genes/riboflavin-mthfr-c677t-blood-pressure Index: https://healthcanon.com/llms.txt · Full text: https://healthcanon.com/llms-full.txt